Preliminary Clinical Experience oftrans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients
Open Access
- 1 June 2014
- journal article
- research article
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-7
Abstract
Background.In this retrospective analysis we assessed the role of [18F]-FACBC-PET/CT in the prostatic cancer staging.Procedure.30 first [18F]-FACBC-PET/CT images of 26 patients (68.1 ± 5.8 years) were analyzed. PET/CT findings were compared with PSA concentrations, with PSA doubling times (PDT), and with correlative imaging.Results.On 16 [18F]-FACBC (53.3%) scans, 58 metabolically active lesions were found. 12 (20.7%) lesions corresponding to the local relapse were found in prostate/prostate bed and seminal vesicles, 9 (15.5%) lesions were located in regional lymph nodes, 10 (17.2%) were located in distal lymph nodes, and 26 (44.8%) metabolically active lesions were found in the skeleton. In one case, focal uptake was found in the brain, confirmed further on MRI as meningioma. The mean S-PSA level in patients with positive [18F]-FACBC findings was 9.5 ± 16.9 μg/L (0.54–69 μg/L) and in patients with negative [18F]-FACBC findings was 1.96 ± 1.87 μg/L (0.11–5.9 μg/L), but the difference was not statistically significant. However, the PSA doubling time (PDT) in patients with positive findings was significantly shorter than PDT in patients with negative findings: 3.25 ± 2.09 months (0.3–6 months) versus 31.2 ± 22.02 months (8–84 months),. There was a strong positive correlation between PSA value and number of metabolically active lesions () and a negative correlation between PDT and number of metabolically active lesions (). There was a weak negative correlation between PDT and().Conclusion.According to our preliminary clinical experience, [18F]-FACBC-PET may play a role inin vivorestaging of an active prostate cancer, especially in patients with a short S-PSA doubling time.
Keywords
This publication has 16 references indexed in Scilit:
- Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancerNuclear Medicine Communications, 2014
- 11C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation TherapyJournal of Nuclear Medicine, 2014
- 11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Volumetric-modulated arc therapy for a pelvic lymph node metastasis from prostate cancer: a case report2013
- Pilot Study of the Utility of the Synthetic PET Amino-Acid Radiotracer Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid for the Noninvasive Imaging of Pulmonary LesionsMolecular Imaging and Biology, 2013
- Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary resultsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and111In–Capromab Pendetide SPECT/CTRadiology, 2011
- Putative Transport Mechanism and Intracellular Fate of Trans-1-Amino-3-18F-Fluorocyclobutanecarboxylic Acid in Human Prostate CancerJournal of Nuclear Medicine, 2011
- Biodistribution and Radiation Dosimetry of the Synthetic Nonmetabolized Amino Acid Analogue Anti-18F-FACBC in HumansJournal of Nuclear Medicine, 2007
- A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer.2007